Embla Medical lands €50M NIB loan to fund prosthetics R&D through 2029
What's the deal? Iceland-based Embla MedicalDealroom has a profile for this one. Try Dealroom → has signed a €50 million, seven-year loan with the Nordic Investment Bank (NIB)Dealroom has a profile for this one. Try Dealroom →. The financing will support the company's research and development programme from 2027 to 2029, focused on prosthetics, orthotics and related healthcare solutions.
What it means. Embla Medical provides prosthetics, orthotics and mobility solutions across more than 120 markets worldwide. The loan will support work on new products, materials, digital technologies and patient care.
Why NIB? The bank is the international financial institution of Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway and Sweden. It finances projects that improve productivity and benefit the Nordic-Baltic region.
Jeanette Vitasp, NIB vice-president and head of lending, said innovation in medical technology plays an important role in improving quality of life and supporting sustainable healthcare systems.
The signal. At €50 million, the deal sits in the top 8% of all debt rounds recorded in the health sector, underlining growing lender appetite for medical technology as an infrastructure play. Backing R&D with debt rather than equity signals confidence in Embla Medical's cash flows and a maturing market for assistive-technology innovation.
Read more: EuropaWire
Image credit: U.S. Department of Defense
